tirzepatide and diabetes for Obesity Prevention Mounjaro (tirzepatide) for the Treatment
Description
doi: 10.1007/s11010-016-2678-1
Frank, R
And remember that medication is just one piece of a comprehensive approach to health
Secondary outcomes of interest included change in sleep apnea-specific hypoxic burden, cardiovascular risk (CV) factors (changes in body weight, systolic blood pressure, and inflammation), and changes in patient-reported sleep troubles
Obesity is a surrogate marker for lack of physical activity and fitness
However, for most people, the significant cost savings far outweigh this minor inconvenience
